GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford Nanopore Technologies PLC (OTCPK:ONTTF) » Definitions » ROE %

Oxford Nanopore Technologies (Oxford Nanopore Technologies) ROE % : -26.31% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Oxford Nanopore Technologies ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Oxford Nanopore Technologies's annualized net income for the quarter that ended in Dec. 2023 was $-213.7 Mil. Oxford Nanopore Technologies's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $812.3 Mil. Therefore, Oxford Nanopore Technologies's annualized ROE % for the quarter that ended in Dec. 2023 was -26.31%.

The historical rank and industry rank for Oxford Nanopore Technologies's ROE % or its related term are showing as below:

ONTTF' s ROE % Range Over the Past 10 Years
Min: -57.22   Med: -37.42   Max: -13.03
Current: -23.43

During the past 6 years, Oxford Nanopore Technologies's highest ROE % was -13.03%. The lowest was -57.22%. And the median was -37.42%.

ONTTF's ROE % is ranked better than
63.69% of 1366 companies
in the Biotechnology industry
Industry Median: -43.41 vs ONTTF: -23.43

Oxford Nanopore Technologies ROE % Historical Data

The historical data trend for Oxford Nanopore Technologies's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Nanopore Technologies ROE % Chart

Oxford Nanopore Technologies Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -58.35 -41.84 -37.59 -12.45 -23.57

Oxford Nanopore Technologies Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only -45.77 -8.12 -17.05 -21.40 -26.31

Competitive Comparison of Oxford Nanopore Technologies's ROE %

For the Biotechnology subindustry, Oxford Nanopore Technologies's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford Nanopore Technologies's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford Nanopore Technologies's ROE % distribution charts can be found below:

* The bar in red indicates where Oxford Nanopore Technologies's ROE % falls into.



Oxford Nanopore Technologies ROE % Calculation

Oxford Nanopore Technologies's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-195.578/( (844.77+815.001)/ 2 )
=-195.578/829.8855
=-23.57 %

Oxford Nanopore Technologies's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-213.692/( (809.609+815.001)/ 2 )
=-213.692/812.305
=-26.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Oxford Nanopore Technologies  (OTCPK:ONTTF) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-213.692/812.305
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-213.692 / 211.812)*(211.812 / 970.8665)*(970.8665 / 812.305)
=Net Margin %*Asset Turnover*Equity Multiplier
=-100.89 %*0.2182*1.1952
=ROA %*Equity Multiplier
=-22.01 %*1.1952
=-26.31 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-213.692/812.305
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-213.692 / -210.656) * (-210.656 / -237.532) * (-237.532 / 211.812) * (211.812 / 970.8665) * (970.8665 / 812.305)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0144 * 0.8869 * -112.14 % * 0.2182 * 1.1952
=-26.31 %

Note: The net income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Oxford Nanopore Technologies ROE % Related Terms

Thank you for viewing the detailed overview of Oxford Nanopore Technologies's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford Nanopore Technologies (Oxford Nanopore Technologies) Business Description

Traded in Other Exchanges
Address
Edmund Halley Road, Gosling Building, Oxford Science Park, Oxford, Oxfordshire, GBR, OX44DQ
Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The Group is primarily involved in researching, developing, manufacturing, and commercializing the world's only commercial nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables our customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science.

Oxford Nanopore Technologies (Oxford Nanopore Technologies) Headlines

From GuruFocus

ONT Chosen for Comprehensive Human Genome Program

By ACCESSWIRE ACCESSWIRE 05-13-2022

Oxford Nanopore Releases Short Fragment Mode

By ACCESSWIRE ACCESSWIRE 03-23-2022

Fastest Human Genome Sequence Uses Oxford Nanopore

By ACCESSWIRE ACCESSWIRE 01-13-2022

Fastest Human Genome Sequence Uses Oxford Nanopore

By ACCESSWIRE ACCESSWIRE 01-13-2022

Oxford Nanopore Announces Technology Updates

By ACCESSWIRE ACCESSWIRE 12-02-2021

Oxford Nanopore Announces Tech Updates

By ACCESSWIRE ACCESSWIRE 05-20-2022

ONT releases Remora: Most Comprehensive Methylation

By ACCESSWIRE ACCESSWIRE 05-26-2022

Genomics England Expands Nanopore Use in Cancer

By ACCESSWIRE ACCESSWIRE 04-04-2022